On the heels of a $6.9B AstraZeneca pact, IP dispute between Daiichi Sankyo and Seattle Genetics rips open in lawsuit
A long-running collaboration on ADC tech with Seattle Genetics that ended 4 years ago has come back to haunt Daiichi Sankyo.
Seven months after AstraZeneca stepped up with a record-setting $6.9 billion deal to license a highly promising cancer drug that appears poised for a near-term approval, Daiichi Sankyo has called up the legal troops to fight back in court against Seattle Genetics’ claim to their IP, stemming from their tech alliance.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,000+ biopharma pros reading Endpoints daily — and it's free.